Oct. 13 at 3:36 PM
Citizens reiterated
$TSHA Market Outperform-
$6 and said, We continue to highlight TSHA as an opportunity based on the efficacy in Rett, clean safety (non-systemic) and regulatory clarity.
$NGNE $ACAD $ALPMY
Citizens JMP added:
A key consideration for investors interested in TSHA has been comparison to NGNE, the most relevant Rett
gene therapy competitor.
We continue to see distinct differences between the Rett clinical strategies of TSHA and NGNE and supportive data:
Overall, both TSHA & NGNE maintain that their asset has better biodistribution with their chosen administration route— intrathecal lumbar (IT-L) for TSHA and intracerebrovascular (ICV) for NGNE.
Based on the more involved procedure required for
ICV administration, we think TSHA has a slight edge on route of administration. In terms of comparison on biodistribution, we think that the clinical data can speak for itself here; both assets appear to deliver gene therapy to the critical brain structures imparting a clinical effect.
